Teriflunomide and Time to Clinical Multiple Sclerosis in Radiologically Isolated Syndrome

Дата публикации: 01-10-2023 00:00:00

This randomized clinical trial investigates the efficacy of the disease-modifying treatment, teriflunomide, in extending the time to a first clinical event in patients with preclinical multiple sclerosis.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis	0	7.35	01-12-2023
2	Deferiprone in Alzheimer Disease	0	10.42	01-01-2025
3	Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	0	8.77	01-04-2024
4	Fecal Microbiota Transplantation for Treatment of Parkinson Disease	0	4.44	01-09-2024
5	Serum GFAP Dynamics, Disease Progression, and Therapy Response in MS	0	8.04	03-08-2026
6	Gefurulimab and Generalized Myasthenia Gravis	0	10.42	27-07-2026
7	Exploratory Tau Biomarker Results From a Study of BIIB080 in Alzheimer Disease	0	10.76	01-12-2023
8	Thousands with MS to get “life-changing” drug on NHS to help them walk more freely	0	6.47	22-07-2026
9	Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke	0	5.05	01-05-2024
10	Efficacy and Safety of Brolucizumab for Diabetic Macular Edema	0	7.97	01-12-2023

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.92. Источник: archderm.jamanetwork.com.